

## SGLT2i: A Comprehensive Approach to Cardio-Renal-Metabolic Disease Management

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have transformed the landscape of chronic disease management by offering benefits that extend far beyond glycemic control. Now recognized as a cornerstone therapy in patients with type 2 diabetes, heart failure, and chronic kidney disease (CKD), SGLT2i provide multi-system protection that addresses the complex interconnection between metabolic dysregulation, cardiovascular disease, and kidney dysfunction.

This presentation explores the evolving role of SGLT2i in managing cardio-renal-metabolic (CRM) disease as a unified clinical entity, rather than as isolated comorbidities. Emphasis will be placed on mechanisms of action that contribute to cardiovascular protection—including preload/afterload reduction, improved myocardial energy utilization, and sympathetic modulation—as well as metabolic outcomes such as weight loss, blood pressure reduction, reducing glucose toxicity and uric acid lowering.

Rather than focusing solely on chronic kidney disease, this session will integrate evidence from major cardiovascular and metabolic trials to highlight how SGLT2i address shared pathophysiological pathways across organ systems. Practical considerations for implementing SGLT2i in patients with overlapping heart failure, diabetes, and CKD will also be discussed.